This Phase 1 open-label study is evaluating the safety of ImmunityBio’s IBRX-042 therapeutic Vaccine in patients with HPV-associated tumors (cervical, esophageal, head, neck, and anal squamous cell carcinomas, as well as vaginal, vulvar, and penile cancers).
